Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 87

1.

Cognitive function in multiple sclerosis: A long-term look on the bright side.

Harel Y, Kalron A, Menascu S, Magalashvili D, Dolev M, Doniger G, Simon E, Achiron A.

PLoS One. 2019 Aug 29;14(8):e0221784. doi: 10.1371/journal.pone.0221784. eCollection 2019.

2.

Mitoxantrone: a review of its use in multiple sclerosis.

Scott LJ, Figgitt DP.

CNS Drugs. 2004;18(6):379-96. Review.

PMID:
15089110
3.

Teriflunomide for multiple sclerosis.

He D, Zhang C, Zhao X, Zhang Y, Dai Q, Li Y, Chu L.

Cochrane Database Syst Rev. 2016 Mar 22;3:CD009882. doi: 10.1002/14651858.CD009882.pub3. Review.

PMID:
27003123
4.

Cognitive impairment and its relation with disease measures in mildly disabled patients with relapsing-remitting multiple sclerosis: baseline results from the Cognitive Impairment in Multiple Sclerosis (COGIMUS) study.

Patti F, Amato MP, Trojano M, Bastianello S, Tola MR, Goretti B, Caniatti L, Di Monte E, Ferrazza P, Brescia Morra V, Lo Fermo S, Picconi O, Luccichenti G; COGIMUS Study Group.

Mult Scler. 2009 Jul;15(7):779-88. doi: 10.1177/1352458509105544.

PMID:
19542262
5.

A combined inspiratory and expiratory muscle training program improves respiratory muscle strength and fatigue in multiple sclerosis.

Ray AD, Udhoji S, Mashtare TL, Fisher NM.

Arch Phys Med Rehabil. 2013 Oct;94(10):1964-70. doi: 10.1016/j.apmr.2013.05.005. Epub 2013 May 25.

PMID:
23714277
6.

The Cannabinoid Use in Progressive Inflammatory brain Disease (CUPID) trial: a randomised double-blind placebo-controlled parallel-group multicentre trial and economic evaluation of cannabinoids to slow progression in multiple sclerosis.

Ball S, Vickery J, Hobart J, Wright D, Green C, Shearer J, Nunn A, Cano MG, MacManus D, Miller D, Mallik S, Zajicek J.

Health Technol Assess. 2015 Feb;19(12):vii-viii, xxv-xxxi, 1-187. doi: 10.3310/hta19120.

7.

Cost analysis of multiple sclerosis in Brazil: a cross-sectional multicenter study.

da Silva NL, Takemoto MLS, Damasceno A, Fragoso YD, Finkelsztejn A, Becker J, Gonçalves MVM, Tilbery C, de Oliveira EML, Callegaro D, Boulos FC.

BMC Health Serv Res. 2016 Mar 24;16:102. doi: 10.1186/s12913-016-1352-3.

8.

The protective effects of high-education levels on cognition in different stages of multiple sclerosis.

Rimkus CM, Avolio IMB, Miotto EC, Pereira SA, Mendes MF, Callegaro D, Leite CDC.

Mult Scler Relat Disord. 2018 May;22:41-48. doi: 10.1016/j.msard.2018.03.001. Epub 2018 Mar 6.

PMID:
29554549
9.

The effect of exercise training in adults with multiple sclerosis with severe mobility disability: A systematic review and future research directions.

Edwards T, Pilutti LA.

Mult Scler Relat Disord. 2017 Aug;16:31-39. doi: 10.1016/j.msard.2017.06.003. Epub 2017 Jun 12. Review.

PMID:
28755682
10.

Patient reported outcomes in benign multiple sclerosis.

Hviid LE, Healy BC, Rintell DJ, Chitnis T, Weiner HL, Glanz BI.

Mult Scler. 2011 Jul;17(7):876-84. doi: 10.1177/1352458511398370. Epub 2011 Mar 3.

PMID:
21372114
11.

Benign multiple sclerosis: physical and cognitive impairment follow distinct evolutions.

Gajofatto A, Turatti M, Bianchi MR, Forlivesi S, Gobbin F, Azzarà A, Monaco S, Benedetti MD.

Acta Neurol Scand. 2016 Mar;133(3):183-91. doi: 10.1111/ane.12442. Epub 2015 May 26.

PMID:
26009804
12.

A longitudinal study of brain atrophy and cognitive disturbances in the early phase of relapsing-remitting multiple sclerosis.

Zivadinov R, Sepcic J, Nasuelli D, De Masi R, Bragadin LM, Tommasi MA, Zambito-Marsala S, Moretti R, Bratina A, Ukmar M, Pozzi-Mucelli RS, Grop A, Cazzato G, Zorzon M.

J Neurol Neurosurg Psychiatry. 2001 Jun;70(6):773-80.

13.

Cognitive impairment after three decades of multiple sclerosis.

Smestad C, Sandvik L, Landrø NI, Celius EG.

Eur J Neurol. 2010 Mar;17(3):499-505. doi: 10.1111/j.1468-1331.2009.02889.x. Epub 2009 Dec 29.

PMID:
20050887
14.

How effective are disease-modifying drugs in delaying progression in relapsing-onset MS?

Brown MG, Kirby S, Skedgel C, Fisk JD, Murray TJ, Bhan V, Sketris IS.

Neurology. 2007 Oct 9;69(15):1498-507. Epub 2007 Aug 15.

PMID:
17699802
15.

Modelling disease progression in relapsing-remitting onset multiple sclerosis using multilevel models applied to longitudinal data from two natural history cohorts and one treated cohort.

Tilling K, Lawton M, Robertson N, Tremlett H, Zhu F, Harding K, Oger J, Ben-Shlomo Y.

Health Technol Assess. 2016 Oct;20(81):1-48.

16.

Dimethyl fumarate for multiple sclerosis.

Xu Z, Zhang F, Sun F, Gu K, Dong S, He D.

Cochrane Database Syst Rev. 2015 Apr 22;(4):CD011076. doi: 10.1002/14651858.CD011076.pub2. Review.

PMID:
25900414
17.

A preliminary validation of the brief international cognitive assessment for multiple sclerosis (BICAMS) tool in an Irish population with multiple sclerosis (MS).

O'Connell K, Langdon D, Tubridy N, Hutchinson M, McGuigan C.

Mult Scler Relat Disord. 2015 Nov;4(6):521-5. doi: 10.1016/j.msard.2015.07.012. Epub 2015 Aug 7.

PMID:
26590658
18.

Rituximab for relapsing-remitting multiple sclerosis.

He D, Guo R, Zhang F, Zhang C, Dong S, Zhou H.

Cochrane Database Syst Rev. 2013 Dec 6;(12):CD009130. doi: 10.1002/14651858.CD009130.pub3. Review.

PMID:
24310855
19.

Predicting caregiving status and caregivers' burden in multiple sclerosis. A short report.

Katsavos S, Artemiadis AK, Zacharis M, Argyrou P, Theotoka I, Chrysovitsanou C, Anagnostouli M.

Neurol Res. 2017 Jan;39(1):13-15. Epub 2016 Nov 9.

PMID:
27825286
20.

Walking and thinking in persons with multiple sclerosis who vary in disability.

Sosnoff JJ, Boes MK, Sandroff BM, Socie MJ, Pula JH, Motl RW.

Arch Phys Med Rehabil. 2011 Dec;92(12):2028-33. doi: 10.1016/j.apmr.2011.07.004.

PMID:
22133253

Supplemental Content

Support Center